WallStreetZenWallStreetZen

NASDAQ: SNGX
Soligenix Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SNGX stock forecasts and price targets.

Forecast return on equity

Is SNGX forecast to generate an efficient return?

Company
-149.97%
Industry
11.17%
Market
145.3%
SNGX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SNGX forecast to generate an efficient return on assets?

Company
-85.94%
Industry
-7.64%
SNGX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SNGX earnings per share forecast

What is SNGX's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.83
Avg 2 year Forecast
-$0.77

SNGX revenue forecast

What is SNGX's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$510.0k
Avg 2 year Forecast
$510.0k

SNGX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SNGX$1.15N/AN/A
GNPX$1.31N/AN/A
GDTC$1.00N/AN/A
CLRB$2.76$10.00+262.32%Strong Buy
BLRX$2.30N/AN/A
View Top Biotech Stocks

Soligenix Stock Forecast FAQ

What is SNGX's earnings growth forecast for 2026-2027?

(NASDAQ: SNGX) Soligenix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,545.36%.

Soligenix's earnings in 2026 is -$11,080,380.On average, 4 Wall Street analysts forecast SNGX's earnings for 2026 to be -$8,567,443, with the lowest SNGX earnings forecast at -$8,584,964, and the highest SNGX earnings forecast at -$8,440,679.

In 2027, SNGX is forecast to generate -$7,936,711 in earnings, with the lowest earnings forecast at -$8,584,964 and the highest earnings forecast at -$7,142,113.

If you're new to stock investing, here's how to buy Soligenix stock.

What is SNGX's revenue growth forecast for 2026-2027?

(NASDAQ: SNGX) Soligenix's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 196.84%.

Soligenix's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast SNGX's revenue for 2026 to be $5,256,100, with the lowest SNGX revenue forecast at $0, and the highest SNGX revenue forecast at $10,821,383.

In 2027, SNGX is forecast to generate $5,256,100 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $10,821,383.

What is SNGX's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: SNGX) forecast ROA is -85.94%, which is lower than the forecast US Biotechnology industry average of -7.64%.

What is SNGX's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: SNGX) Soligenix's current Earnings Per Share (EPS) is -$2.14. On average, analysts forecast that SNGX's EPS will be -$0.83 for 2026, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.82. In 2027, SNGX's EPS is forecast to hit -$0.77 (min: -$0.83, max: -$0.69).

What is SNGX's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: SNGX) forecast ROE is -149.97%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.